Celgene Corporation says that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for label expansions of its oncology drug, Revlimid and Imnovid.
The CHMP recommended approval of the triplet regimen of Revlimid as combination therapy with Velcade and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The European Commission generally follows the recommendation of the CHMP but is not bound by it. The committee is expected to make its final decision in approximately two months.
a developer of human pharmaceuticals and agrochemicals
Industry Biotechnology